Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Prostate Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 60 articles: HTML format

Single Articles

November 2025
1. CHEN J, Wang ME, Bawcom AR, Lu Y, et al
   Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation.
   Oncogene. 2025;44:4405-4412.
   PubMed     Abstract available
   
   
   October 2025
2. CHERIF C, Nguyen DT, Paris C, Le TK, et al
   Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
   Oncogene. 2025 Oct 28. doi: 10.1038/s41388-025-03614.
   PubMed    
   
   
   September 2025
3. SHENG H, Shi G, Lu Y, Zheng S, et al
   KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer.
   Oncogene. 2025 Sep 23. doi: 10.1038/s41388-025-03576.
   PubMed     Abstract available
   
   
   
4. GE Y, Han P, Sun Y, Chen Y, et al
   Aging-associated ZNF573 methylation regulates RNF19B-PIK3CA ubiquitination to promote prostate cancer.
   Oncogene. 2025 Sep 19. doi: 10.1038/s41388-025-03579.
   PubMed     Abstract available
   
   
   
5. CHUKHU M, Dahiya UR, Heemers HV
   Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer.
   Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03573.
   PubMed     Abstract available
   
   
   
6. RAZA M, Rajan AR, Kennedy BB, Reznicek TE, et al
   ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.
   Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03559.
   PubMed     Abstract available
   
   
   
7. CIVENNI G, Sandrini G, Merulla J, Musumeci C, et al
   Integrated control of cancer stemness by sigma(1) receptor in advanced prostate cancer.
   Oncogene. 2025 Sep 2. doi: 10.1038/s41388-025-03541.
   PubMed     Abstract available
   
   
   August 2025
8. TONG T, Lei H, Huang M, Yang Z, et al
   HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer.
   Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03548.
   PubMed     Abstract available
   
   
   
9. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
   Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
   Oncogene. 2025 Aug 7. doi: 10.1038/s41388-025-03531.
   PubMed    
   
   
   
10. HAO JL, He JQ, Hu H, Zhu ZH, et al
    TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity.
    Oncogene. 2025 Aug 4. doi: 10.1038/s41388-025-03517.
    PubMed     Abstract available
    
    
    
11. SANCHIS P, Sabater A, Lechuga J, Rada J, et al
    PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression.
    Oncogene. 2025 Aug 2. doi: 10.1038/s41388-025-03511.
    PubMed     Abstract available
    
    
    July 2025
12. HUO D, Si M, Yu K, Fang X, et al
    Increased antiandrogen enzalutamide sensitivity via altering prostate cancer stem cell traits through modulating the androgen receptor-mediated CDR1/circCDR1-AS/miR-1290/BMP4 signaling.
    Oncogene. 2025 Jul 4. doi: 10.1038/s41388-025-03482.
    PubMed     Abstract available
    
    
    April 2025
13. WALKE P, Price JDW, Vizeacoumar FS, Joseph N, et al
    A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer.
    Oncogene. 2025 Apr 29. doi: 10.1038/s41388-025-03413.
    PubMed     Abstract available
    
    
    
14. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
    Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03407.
    PubMed    
    
    
    
15. YANG JC, Xu P, Ning S, Wasielewski LJ, et al
    Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03392.
    PubMed    
    
    
    March 2025
16. HOFSTAD M, Woods A, Parra K, Sychev ZE, et al
    Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer.
    Oncogene. 2025 Mar 21. doi: 10.1038/s41388-025-03343.
    PubMed     Abstract available
    
    
    
17. YIN L, Dai Y, Wang Y, Liu S, et al
    A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.
    Oncogene. 2025 Mar 6. doi: 10.1038/s41388-025-03328.
    PubMed     Abstract available
    
    
    
18. SCHMIDT MJ, Naghdloo A, Prabakar RK, Kamal M, et al
    Polyploid cancer cells reveal signatures of chemotherapy resistance.
    Oncogene. 2025;44:439-449.
    PubMed     Abstract available
    
    
    January 2025
19. KAUSHAL JB, Raut P, Halder S, Alsafwani ZW, et al
    Oncogenic potential of truncated-Gli3 via the Gsk3beta/Gli3/AR-V7 axis in castration-resistant prostate cancer.
    Oncogene. 2025 Jan 16. doi: 10.1038/s41388-024-03266.
    PubMed     Abstract available
    
    
    December 2024
20. DUTTA S, Khedmatgozar H, Patel GK, Latour D, et al
    A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.
    Oncogene. 2024 Dec 20. doi: 10.1038/s41388-024-03252.
    PubMed     Abstract available
    
    
    
21. WOYTASH JA, Kumar R, Chaudhary AK, Donnelly C, et al
    Mitochondrial unfolded protein response-dependent beta-catenin signaling promotes neuroendocrine prostate cancer.
    Oncogene. 2024 Dec 17. doi: 10.1038/s41388-024-03261.
    PubMed     Abstract available
    
    
    November 2024
22. HUANG F, Li K, Chen Z, Cui Z, et al
    Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer.
    Oncogene. 2024 Nov 29. doi: 10.1038/s41388-024-03239.
    PubMed     Abstract available
    
    
    
23. RODRIGUES SOUSA E, de Brot S, Zoni E, Zeinali S, et al
    CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.
    Oncogene. 2024 Nov 26. doi: 10.1038/s41388-024-03230.
    PubMed     Abstract available
    
    
    
24. LYU C, Vaddi PK, Elshafae S, Pradeep A, et al
    Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development.
    Oncogene. 2024 Nov 13. doi: 10.1038/s41388-024-03224.
    PubMed     Abstract available
    
    
    
25. SHARMA S, Pei X, Xing F, Wu SY, et al
    Correction: Regucalcin promotes dormancy of prostate cancer.
    Oncogene. 2024 Nov 11. doi: 10.1038/s41388-024-03216.
    PubMed    
    
    
    
26. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    Correction: AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03190.
    PubMed    
    
    
    
27. OFFENHAUSER C, Dave KA, Beckett KJ, Smith FM, et al
    EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylation.
    Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03206.
    PubMed     Abstract available
    
    
    
28. HUANG H, Zhuang X, Yin S, Sun W, et al
    The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer.
    Oncogene. 2024 Nov 2. doi: 10.1038/s41388-024-03209.
    PubMed     Abstract available
    
    
    
29. RHEE JW, Adzavon YM, Sun Z
    Stromal androgen signaling governs essential niches in supporting prostate development and tumorigenesis.
    Oncogene. 2024;43:3419-3425.
    PubMed     Abstract available
    
    
    October 2024
30. WANG K, Chen M, Yan S, Han Y, et al
    Zinc ions activate AKT and promote prostate cancer cell proliferation via disrupting AKT intramolecular interaction.
    Oncogene. 2024 Oct 23. doi: 10.1038/s41388-024-03195.
    PubMed     Abstract available
    
    
    
31. LIN G, Tian F, Yu Q, Weng X, et al
    IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.
    Oncogene. 2024 Oct 18. doi: 10.1038/s41388-024-03169.
    PubMed     Abstract available
    
    
    
32. XIONG X, Zhang S, Zhu W, Du J, et al
    Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support progression of androgen receptor negative prostate cancer cells.
    Oncogene. 2024 Oct 5. doi: 10.1038/s41388-024-03181.
    PubMed     Abstract available
    
    
    September 2024
33. MU Y, Wallenius A, Zang G, Zhu S, et al
    The TbetaRI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells.
    Oncogene. 2024 Sep 20. doi: 10.1038/s41388-024-03165.
    PubMed     Abstract available
    
    
    
34. SARDAR S, McNair CM, Ravindranath L, Chand SN, et al
    AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Oncogene. 2024 Sep 13. doi: 10.1038/s41388-024-03148.
    PubMed     Abstract available
    
    
    August 2024
35. YU J, Zhang M, Li T, Gao W, et al
    Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-kappaB activation and promotes docetaxel efficacy in prostate cancer.
    Oncogene. 2024 Aug 18. doi: 10.1038/s41388-024-03132.
    PubMed     Abstract available
    
    
    
36. XIONG S, Li S, Li Z, Song Y, et al
    A noncanonical E3 ubiquitin ligase RNF41-mediated MYO1C stability promotes prostate cancer metastasis by inducing actin remodeling.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03120.
    PubMed     Abstract available
    
    
    July 2024
37. JIN Z, Wang H, Tang R, Pan B, et al
    GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-beta axis-mediated antitumor immunity.
    Oncogene. 2024 Jul 27. doi: 10.1038/s41388-024-03107.
    PubMed     Abstract available
    
    
    June 2024
38. LIN G, Zhang F, Weng X, Hong Z, et al
    Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models.
    Oncogene. 2024 Jun 17. doi: 10.1038/s41388-024-03073.
    PubMed     Abstract available
    
    
    
39. CHEN B, Xu P, Yang JC, Nip C, et al
    Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
    Oncogene. 2024 Jun 14. doi: 10.1038/s41388-024-03081.
    PubMed     Abstract available
    
    
    
40. FRANCIS JC, Capper A, Rust AG, Ferro K, et al
    Identification of genes that promote PI3K pathway activation and prostate tumour formation.
    Oncogene. 2024;43:1824-1835.
    PubMed     Abstract available
    
    
    May 2024
41. ZHAO J, Shen J, Mao L, Yang T, et al
    Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03057.
    PubMed     Abstract available
    
    
    
42. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
    AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
    Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03064.
    PubMed     Abstract available
    
    
    
43. BEIER AK, Ebersbach C, Siciliano T, Scholze J, et al
    Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer.
    Oncogene. 2024 May 15. doi: 10.1038/s41388-024-03059.
    PubMed     Abstract available
    
    
    April 2024
44. RAWAT C, Heemers HV
    Alternative splicing in prostate cancer progression and therapeutic resistance.
    Oncogene. 2024 Apr 24. doi: 10.1038/s41388-024-03036.
    PubMed     Abstract available
    
    
    
45. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    Correction: In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Apr 16. doi: 10.1038/s41388-024-03031.
    PubMed    
    
    
    
46. LI Y, Lv L, Ye M, Xie N, et al
    PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
    Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024.
    PubMed     Abstract available
    
    
    
47. CHEN M, Zou C, Tian Y, Li W, et al
    An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
    PubMed     Abstract available
    
    
    March 2024
48. YI Q, Han X, Yu HG, Chen HY, et al
    SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
    PubMed     Abstract available
    
    
    
49. GUO S, Miao M, Wu Y, Pan D, et al
    DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
    Oncogene. 2024 Mar 13. doi: 10.1038/s41388-024-03005.
    PubMed     Abstract available
    
    
    
50. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Mar 7. doi: 10.1038/s41388-024-02995.
    PubMed     Abstract available
    
    
    
51. LI J, Hong Z, Zhang J, Zheng S, et al
    Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
    Oncogene. 2024;43:744-757.
    PubMed     Abstract available
    
    
    January 2024
52. CHAO Y, Chen Y, Zheng W, Demanelis K, et al
    Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Oncogene. 2024 Jan 25. doi: 10.1038/s41388-024-02939.
    PubMed     Abstract available
    
    
    
53. RODRIGUEZ TIRADO C, Wang C, Li X, Deng S, et al
    UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
    Oncogene. 2024;43:265-280.
    PubMed     Abstract available
    
    
    December 2023
54. FERRARI MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, et al
    Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
    Oncogene. 2023 Dec 23. doi: 10.1038/s41388-023-02925.
    PubMed     Abstract available
    
    
    
55. MILLER KA, Degan S, Wang Y, Cohen J, et al
    Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02920.
    PubMed    
    
    
    
56. CHAUHAN SS, Casillas AL, Vizzerra AD, Liou H, et al
    PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02914.
    PubMed     Abstract available
    
    
    November 2023
57. EIGENTLER A, Handle F, Schanung S, Degen A, et al
    Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02901.
    PubMed     Abstract available
    
    
    
58. CUI H, Wang Y, Zhou T, Qu L, et al
    Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress.
    Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02878.
    PubMed     Abstract available
    
    
    October 2023
59. MILLER KA, Degan S, Wang Y, Cohen J, et al
    PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Oct 24. doi: 10.1038/s41388-023-02875.
    PubMed     Abstract available
    
    
    September 2023
60. ADVANI R, Luzzi S, Scott E, Dalgliesh C, et al
    Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer.
    Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.